Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
 
Generic Name:  Imatinib mesylate
Trade Name:  Gleevec
Date Designated:  08/25/2005
Orphan Designation:  Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia
Orphan Designation Status:  Designated/Approved
Marketing Approval Date:  10/19/2006 
Approved Labeled Indication:  Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRÿ}ÿ± fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRÿ}ÿ± fusion kinase negative or unknown
Exclusivity End Date:    10/19/2013 
Exclusivity Protected Indication* :  
Novartis Pharmaceuticals Corporation
One Health Plaza
Mail Code 105/1E870D
East Hanover, New Jersey 07936
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-